Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nuvation Bio Inc (NUVB)

Nuvation Bio Inc (NUVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,542,749
  • Shares Outstanding, K 342,833
  • Annual Sales, $ 62,900 K
  • Annual Income, $ -204,630 K
  • EBIT $ -213 M
  • EBITDA $ -211 M
  • 60-Month Beta 1.49
  • Price/Sales 24.20
  • Price/Cash Flow N/A
  • Price/Book 4.98

Options Overview Details

View History
  • Implied Volatility 109.53% (+10.23%)
  • Historical Volatility 95.23%
  • IV Percentile 52%
  • IV Rank 8.07%
  • IV High 585.10% on 04/08/25
  • IV Low 67.79% on 07/22/25
  • Expected Move (DTE 2) 0.72 (16.42%)
  • Put/Call Vol Ratio 0.07
  • Today's Volume 2,006
  • Volume Avg (30-Day) 1,359
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 92,212
  • Open Int (30-Day) 88,349
  • Expected Range 3.68 to 5.12

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.04
  • Number of Estimates 4
  • High Estimate 0.75
  • Low Estimate -0.47
  • Prior Year -0.16
  • Growth Rate Est. (year over year) +125.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.16 +5.77%
on 03/03/26
6.00 -26.67%
on 02/18/26
-1.48 (-25.17%)
since 02/17/26
3-Month
4.16 +5.77%
on 03/03/26
9.75 -54.87%
on 12/22/25
-4.12 (-48.36%)
since 12/17/25
52-Week
1.54 +185.71%
on 04/07/25
9.75 -54.87%
on 12/22/25
+2.31 (+110.53%)
since 03/17/25

Most Recent Stories

More News
Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026

Clinical data demonstrate IBTROZI's unprecedented durability in TKI-naïve advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC), with median Duration of Response (DOR) now increased to...

NUVB : 4.40 (-2.22%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB

NEW YORK , March 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nuvation Bio Inc. ("Nuvation" or the "Company") (NYSE: NUVB).  Such investors are advised...

NUVB : 4.40 (-2.22%)
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm

NEW YORK , March 6, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nuvation Bio Inc. (NYSE: NUVB) ...

NUVB : 4.40 (-2.22%)
Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Successfully started 216 patients on IBTROZI ® (taletrectinib) in the fourth quarter of 2025, for a total of 432 new patient starts since launch in the second half of June 2025

NUVB : 4.40 (-2.22%)
Nuvation Bio to Participate in Upcoming Investor Conferences

NEW YORK , Feb. 25, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David...

NUVB : 4.40 (-2.22%)
Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026

NEW YORK , Feb. 17, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will...

NUVB : 4.40 (-2.22%)
Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma

Protocol amendment to change SIGMA from a Phase 2 to a Phase 3 study now complete The currently enrolling SIGMA trial will now include patients with grade 2 astrocytoma...

NUVB : 4.40 (-2.22%)
Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference

Successfully started 216 patients on IBTROZI ® (taletrectinib) in the fourth quarter of 2025, for a total of 432 new patient starts since launch in the second half of June 2025 ...

NUVB : 4.40 (-2.22%)
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan

Strategic collaboration expands taletrectinib global reach with a leading oncology partner Eisai will receive exclusive development, registration and commercialization...

NUVB : 4.40 (-2.22%)
Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive...

NUVB : 4.40 (-2.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Nuvation Bio Inc. is a biopharmaceutical company. It engages in developing differentiated and novel therapeutic candidates for unmet needs in oncology. Nuvation Bio Inc., formerly known as Panacea Acquisition Corp., is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 4.81
2nd Resistance Point 4.71
1st Resistance Point 4.55
Last Price 4.40
1st Support Level 4.29
2nd Support Level 4.19
3rd Support Level 4.03

See More

52-Week High 9.75
Fibonacci 61.8% 6.61
Fibonacci 50% 5.64
Fibonacci 38.2% 4.68
Last Price 4.40
52-Week Low 1.54

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar